A Study of GSK256073 in Subjects With Type 2 Diabetes Mellitus Who Are Being Treated With Metformin
Status:
Completed
Trial end date:
2012-09-17
Target enrollment:
Participant gender:
Summary
The aim of this combined, two part study is to evaluate the safety and glucose lowering
effects of GSK256073 when administered to diabetic subjects for 12 weeks.